Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

April 10, 2023

Study Completion Date

April 10, 2023

Conditions

Advanced Malignant Tumor

Interventions

DRUG

LBL-003 Injection

LBL-003 was given every two weeks for treatment

Trial Locations (3)

Shangdong Cancer Hospital, Jinan

Hunan Cancer Hospital, Changsha

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Hunan Cancer Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY

NCT05042908 - Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter